Question

Trecek Corporation incurs research and development costs of $695,000 in 2017, 30 percent of which relate to development activities subsequent to IAS 38 criteria having been met that indicate an intangible asset has been created. The newly developed product is brought to market in January 2018 and is expected to generate sales revenue for 10 years.

Assume that a U.S based company is issuing securities to foreign investors who require financial statements prepared in accordance with IFRS. Thus, adjustments to convert from U.S. GAAP to IFRS must be made. Ignore income taxes.

Requried:

a. Prepare journal entries for research and development costs for the years ending December 31, 2017, and December 31, 2018, under (1) U.S. GAAP and (2) IFRS.

(1) Record the research and development costs as per U.S. GAAP

(2) Record the research and development costs as per IRFS

(3) Record the amortization expense as per U.S. GAAP

(4) Record the amortization expense as per IFRS.

b. Prepare the entry(ies) that Trecek would make on the December 31, 2017, and December 31, 2018, conversion worksheets to conver U.S. GAAP balances to IFRS

(1) Record the conversion entry needed for the research and development costs for 12/31/17

(2) Record the conversion entry needed for the research and development costs for 12/31/18

(3) Record the conversion entry needed for the amortization expense for 12/31/18

Answer 1

A)

2) & 4)

Treatment of research and development costs as per IFRS

Journal Entries for the year ended 2017

Research Expense A/c Dr.$486500($695000*70/100)

To Bank/Cash A/c Cr $486500

The Above should be go to Profit and Loss Account.

Development A/c Dr$208500($695000*30/100)

To Bank/Cash Cr $208500

So as per IAS 38 Research expenditure should be immediately expensed out as and when occured as it does not satisfy the Recognition criteria. Development Expenditure should be Capitalised and show $208500 in Balance sheet under asset side and should be amortised from 2018 on a systemetic basis. Here is the period of expected sales that is 10 years.

Journal Entry in 2018

P&L A/c Dr$20850(208500/10 years)

To Development Expense$20850

1) & 3) Treatment Under US GAAP

All cost should be expensed out in P&L Account regardless of wheher it is Development cost, so the whole expenditure should be expensed out.

Research& Development Expense A/c Dr $695000

To Bank/Cash Cr Cr $695000